Cap binding complexes and cellular growth control.

S Mader; N Sonenberg

doi:10.1016/0300-9084(96)88102-8

Home/Archive/PubMed

PubMed · 7599274

Cap binding complexes and cellular growth control.

S Mader·N Sonenberg

View original source ↗Export metadata ↓

Abstract

The cap-binding complex eIF-4F plays a major role in the control of translation initiation, and overexpression of its limiting subunit, eIF-4E, leads to the deregulation of cellular growth. The recent cloning of eIF-4E binding proteins (4E-BPs) has uncovered a previously unsuspected pathway for the regulation of eIF-4E activity, through sequestration of eIF-4E as a complex with 4E-BPs.

Explore related subjects

Cell Division Eukaryotic Initiation Factor-4E Eukaryotic Initiation Factor-4F Gene Expression Regulation Peptide Initiation Factors Phosphorylation Protein Biosynthesis RNA Cap-Binding Proteins RNA Caps RNA-Binding Proteins Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

S Mader, N Sonenberg. 1995. Cap binding complexes and cellular growth control.. https://doi.org/10.1016/0300-9084(96)88102-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Loss of prohibitins, though it shortens the replicative life span of yeast cells undergoing division, does not shorten the chronological life span of G0-arrested cells.

Prohibitin proteins have been implicated in cell proliferation, ageing and the maintenance of mitochondrial integrity. The yeast prohibitins, Phb1p and Phb2p, are close in sequence to their two human counterparts, prohibitin and BAP37. Mutants of Saccharomyces cerevisiae that lack these prohibitins have a shortened replicative (budding) life span. Nevertheless, their chronological life span, measured as the survival of stationary phase (G0) cells over time, is essentially normal. Loss of prohibitins does not hypersensitise cells to their endogenous free radical production, though it does slightly increase their sensitivity to ethanol. It is unlikely, therefore, that the influences of prohibitins over replicative senescence involve free radicals, despite the evidence from many systems linking ageing to the long-term effects of oxidative stress. Yeast phb1 and phb2 mutants and also the phb1, phb2 double mutant, tend to lose respiration competence when in G0-arrest, indicating that nondividing cells lacking prohibitins have problems maintaining a functional mitochondrial electron transport chain. This may reflect an imbalance in the turnover of components of the respiratory chain in G0 cells, since the Phb1/2p complex is known to help stabilise these components. Such losses of respiratory function in G0-arrested cells are greater with the loss of Phb1p than with the loss of Phb2p, revealing the Phb1p null and Phb2p null phenotypes to be nonidentical.

Cell Division↗

PubMed2001

A highly selective telomerase inhibitor limiting human cancer cell proliferation.

Telomerase, the ribonucleoprotein enzyme maintaining the telomeres of eukaryotic chromosomes, is active in most human cancers and in germline cells but, with few exceptions, not in normal human somatic tissues. Telomere maintenance is essential to the replicative potential of malignant cells and the inhibition of telomerase can lead to telomere shortening and cessation of unrestrained proliferation. We describe novel chemical compounds which selectively inhibit telomerase in vitro and in vivo. Treatment of cancer cells with these inhibitors leads to progressive telomere shortening, with no acute cytotoxicity, but a proliferation arrest after a characteristic lag period with hallmarks of senescence, including morphological, mitotic and chromosomal aberrations and altered patterns of gene expression. Telomerase inhibition and telomere shortening also result in a marked reduction of the tumorigenic potential of drug-treated tumour cells in a mouse xenograft model. This model was also used to demonstrate in vivo efficacy with no adverse side effects and uncomplicated oral administration of the inhibitor. These findings indicate that potent and selective, non-nucleosidic telomerase inhibitors can be designed as novel cancer treatment modalities.

Cell Division↗

PubMed2001

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro and in vivo, of human cancer cell lines expressing various levels of EGFR and erbB2. Proliferation of EGFR-overexpressing A431 and MDA-MB-231 cells in vitro was potently inhibited (50%-70%) by ZD1839 with half-maximally effective doses in the low nanomolar range. In parallel, ZD1839 blocked autophosphorylation of EGFR and prevented activation of PLC-gamma 1, ERK MAP kinases and PKB/Akt by EGF. It also inhibited proliferation in EGFR(+) cancer cell lines overexpressing erbB2 (SKBr3, SKOV3, BT474) by between 20% and 80%, effects which correlated with inhibition of EGF-dependent erbB2 phosphorylation and activation of ERK MAP kinase and PKB/Akt in SKOV3 cells. Oral administration of ZD1839 inhibited the growth of MDA-MB-231 and SKOV3 tumours, established as xenografts in athymic mice, by 71% and 32%, respectively. Growth inhibition coincided with reduced proliferation but no change in apoptotic index. Collectively, these results show that ZD1839, at the doses studied, is a potent inhibitor of proliferation not only in cells overexpressing EGFR but also in EGFR(+) cells that overexpress erbB2.

Cell Division↗